ALMR Company Profile and Key Details

Average 10-day trading volume of 653.52 thousand shares is significantly above the 3-month average of 369.95 thousand, indicating heightened recent market interest.

Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $35.00 to $28.00. The high target offers 0.43% upside. The low target suggests -19.66% downside. The mean target is $30.75. This offers -11.76% upside. Alamar Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended August 10, 2026, missed forecasts by -28.54%. The prior quarter beat by 1.75%. Over the last six quarters, Apple has recorded several small beats. These include 1.75% in May 08, 2026.

Alamar Biosciences, Inc. has 69.39 million shares outstanding. The public float is 36.16 million shares, elevated short interest at 4.96% of float. This equals 2.12 million shares. The short ratio is 6.02 days. Institutional investors hold 48.42% of the float. Insiders own 26.67%.

Alamar Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.45. This means the shares are trading above this model’s fair value.

Alamar Biosciences, Inc. (NASDAQ:ALMR) closed at $34.85 USD, gaining $2.84 (8.87%) from the previous close of $32.01. The stock is currently mid-range between its 52-week high and low $18.85 and $38.54. With a market capitalization of about $2.42 billion, Alamar Biosciences, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~-6.18). Key stats such as the average daily volume over the past year has been around 368.78 thousand shares, trading with heavier-than-usual volume. Headquartered in Fremont, CA, Alamar Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Yuling Luo, the company employs approximately 222 people and listed since April 17, 2026. Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications.

Our AI price prediction model suggests that Alamar Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.83%, with price expected at $30.38 by October 02, 2026, within a range of $28.39 to $32.33 3-Month Outlook: Projected fall of -83.41%, reaching $5.78 by December 17, 2026, with a range of $5.43 to $6.15. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by September 17, 2027, within a range of $0.00 to $0.00.

Valuation shows Alamar Biosciences, Inc. trading at a premium to the broader market with a P/E of -65.75. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $30.75, suggesting -11.76% downside. Our AI forecast model points to short-term weakness (-12.83% over two weeks), a medium-term fall (-83.41% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Alamar Biosciences, Inc. trades at a P/E ratio of -65.75, slightly below the S&P 500 average, with a price-to-sales ratio of 43.55 and a price-to-book ratio of 6.53 trading at moderately above to book value. The P/FCF stands at -67.26, also below market averages.